Advertisement

Topics

Treatment of type 2 diabetes: future approaches.

08:00 EDT 1st June 2018 | BioPortfolio

Summary of "Treatment of type 2 diabetes: future approaches."

Type 2 diabetes, which accounts for ~90% of all diabetes, is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycaemia of type 2 diabetes is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments.

Affiliation

Journal Details

This article was published in the following journal.

Name: British medical bulletin
ISSN: 1471-8391
Pages: 123-137

Links

DeepDyve research library

PubMed Articles [33276 Associated PubMed Articles listed on BioPortfolio]

Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes.

Diabetes mellitus is a heterogeneous group of conditions defined by resultant chronic hyperglycemia. Given the increasing prevalence of diabetes mellitus and the increasing understanding of genetic et...

The evolution of type 2 diabetes treatment approaches.

No abstract is available for this article. This article is protected by copyright. All rights reserved.

Prevalence of Diagnosed Diabetes in Adults by Diabetes Type - United States, 2016.

Currently 23 million U.S. adults have been diagnosed with diabetes (1). The two most common forms of diabetes are type 1 and type 2. Type 1 diabetes results from the autoimmune destruction of the panc...

Emerging Approaches in Surveillance of Type 1 Diabetes.

Surveillance of type 1 diabetes provides an opportunity to address public health needs, inform etiological research, and plan health care services. We present issues in type 1 diabetes surveillance, r...

Comorbidity Type and Health Care Costs in Type 2 Diabetes: A Retrospective Claims Database Analysis.

Previous studies suggest that the type and combination of comorbidities may impact diabetes care, but their cost implications are less clear. This study characterized how diabetes patients' health car...

Clinical Trials [10650 Associated Clinical Trials listed on BioPortfolio]

Polyneuropathy in Diabetes Mellitus Type 2

This is a population-based study of type 2 diabetes patients with and without neuropathy recruited from the Danish National Type 2 Diabetes cohort (DD2). Perspective: The study will ident...

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle approa...

A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)

The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabet...

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine...

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

The study hypothesis is that XOMA 052 improves glycemic control in subjects with Type 2 Diabetes. Study X052078 is designed to establish efficacious dose(s) for future studies based on ...

Medical and Biotech [MESH] Definitions

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

A method of providing future reproductive opportunities before a medical treatment with known risk of loss of fertility. Typically reproductive organs or tissues (e.g., sperm, egg, embryos and ovarian or testicular tissues) are cryopreserved for future use before the medical treatment (e.g., chemotherapy, radiation) begins.

Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.

A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article